ARCH VENTURE FUND XII, L.P. - RAPPORT THERAPEUTICS, INC. -- SCH 13G

Company

Rapport Therapeutics, Inc.

Filed

November 14, 2024

Accession Number

0001072613-24-000885

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →